Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type (Viral Vector, Non-Viral Vector), By Delivery Method (In-Vivo, Ex-Vivo), By Indication (Rare Diseases, Cancer, Neurological Diseases, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.54 Billion
CAGR (2026-2031)	9.53%
Fastest Growing Segment	Non-viral vectors
Largest Market	North America
Market Size (2031)	USD 13.02 Billion

Market Overview

The Global Gene Therapy Market will grow from USD 7.54 Billion in 2025 to USD 13.02 Billion by 2031 at a 9.53% CAGR. Gene therapy is defined as a medical intervention that modifies the genetic instructions within a person's cells to treat or prevent disease by replacing, inactivating, or introducing genes. The expansion of this market is primarily driven by the rising incidence of rare genetic conditions and chronic diseases which creates urgent demand for durable therapeutic solutions. Furthermore, advancements in viral vector technologies and streamlined regulatory designations expedite the approval process and facilitate the translation of clinical research into commercial products.

Despite this progress, the high complexity of manufacturing and the associated costs pose a significant challenge to market scalability and accessibility. These economic factors often result in pricing structures that strain healthcare reimbursement systems and limit patient adoption. According to the American Society of Gene & Cell Therapy, in the second quarter of 2025, oncology indications accounted for 64% of the 80 newly initiated gene therapy clinical trials. This statistic highlights the sector's continued clinical focus on complex indications despite the financial barriers.

Key Market Drivers

Supportive regulatory frameworks and expedited approval pathways are fundamentally reshaping the market by accelerating the commercialization of novel treatments. Regulatory agencies have adopted specialized designations, such as the FDA's RMAT and Breakthrough Therapy status, which streamline the review process for complex biologic products and reduce the timeline between clinical validation and patient access. This pro-innovation stance has catalyzed a tangible increase in successful market entries, effectively validating emerging viral vector and gene-editing technologies. According to Fierce Pharma, January 2026, the FDA granted approval to nine new cell and gene therapies in 2024, marking a record high for the sector. These regulatory milestones de-risk future development programs and encourage sustained industrial participation by demonstrating a clear, navigable path to commercialization.

A surge in investment and funding for life sciences research further propels market expansion, providing the essential capital required for high-cost clinical development and manufacturing scale-up. Biopharmaceutical developers continue to secure substantial financial backing to advance their pipelines, ensuring that innovative candidates can progress through rigorous testing phases despite broader economic fluctuations. According to the Alliance for Regenerative Medicine, January 2025, the sector attracted $15.2 billion in global investment in 2024, representing a 30% increase year-over-year. This influx of capital supports a diverse and expanding ecosystem of therapeutic options targeting a wide range of diseases. According to the American Society of Gene & Cell Therapy, in November 2025, the global pipeline comprised more than 3,200 active clinical trials for gene, cell, and RNA therapies.

Download Free Sample Report

Key Market Challenges

The high complexity of manufacturing and the associated costs constitute a formidable barrier that directly impedes the scalability and commercial potential of the Global Gene Therapy Market. Unlike small-molecule drugs, gene therapies rely on intricate biological processes, such as viral vector production, which are inherently difficult to standardize and scale. This lack of manufacturing efficiency results in exorbitant Cost of Goods Sold (COGS), forcing companies to set high list prices that strain healthcare budgets. Consequently, payers often impose strict reimbursement criteria, which limits patient access and reduces the revenue potential necessary to sustain further innovation.

The capital-intensive nature of overcoming these manufacturing hurdles also creates a challenging financial environment for developers. Establishing Good Manufacturing Practice (GMP) compliant facilities requires massive upfront capital, draining resources that could otherwise fund pipeline expansion. According to the Alliance for Regenerative Medicine, in the first half of 2024, the sector raised approximately $10.9 billion in investment. While this funding is substantial, the extreme costs associated with biomanufacturing and supply chain logistics mean that a significant portion of this capital is absorbed by operational expenses rather than clinical advancement, thereby slowing the overall rate of market growth and product commercialization.

Key Market Trends

The Proliferation of Strategic Partnerships with CDMOs is addressing critical manufacturing bottlenecks. By outsourcing to Contract Development and Manufacturing Organizations, developers access specialized viral vector infrastructure without the prohibitive capital costs of internal facilities. This strategy mitigates technical risks and expedites clinical validation through established regulatory pathways, allowing innovators to focus resources on pipeline development rather than process engineering. According to Matica Biotechnology, October 2025, in the 'Matica Biotechnology Emerges as the Go-To CDMO' press release, the company secured over 10 new manufacturing projects in the first half of 2025, reflecting the sector's rapid adoption of externalized production to support expanding pipelines.

Simultaneously, the Shift From Ex Vivo to Direct In Vivo Administration Routes is transforming the therapeutic landscape for complex tissue targets. Unlike ex vivo methods limited to accessible cells, direct in vivo delivery utilizes advanced vectors to treat deep anatomical sites such as the central nervous system. This approach simplifies logistics and extends the reach of gene therapy to previously untreatable neurological conditions. According to the International Society for Cell & Gene Therapy, January 2025, in the article 'Cell & Gene Therapy Approvals in 2024', the approval of Kebilidi marked a milestone as the first gene therapy directly administered to the brain, confirming the viability of this administration route.

Segmental Insights

The non-viral vectors segment represents the fastest-growing category in the Global Gene Therapy Market due to distinct safety and production advantages. These vectors induce fewer immune responses compared to viral alternatives, significantly lowering the risk of adverse effects for patients. Furthermore, non-viral methods support larger genetic loads and offer cost-effective scalability, which resolves common manufacturing bottlenecks found with viral systems. This growth is reinforced by favorable guidelines from the US FDA regarding safer delivery mechanisms, encouraging manufacturers to adopt these technologies for treating chronic conditions.

Regional Insights

North America holds a dominant share of the global gene therapy market, driven by a high concentration of key biotechnology companies and extensive research infrastructure. The region benefits from a supportive regulatory environment, where the United States Food and Drug Administration facilitates product development through established approval pathways. Additionally, the rising prevalence of rare genetic disorders and chronic diseases fuels demand for effective treatments. Well-structured reimbursement policies and substantial healthcare expenditure further enable the successful commercialization and patient adoption of these therapies throughout the region.

Recent Developments

• In December 2024, PTC Therapeutics entered into a major global license and collaboration agreement with Novartis to accelerate the development of a huntingtin-lowering gene therapy program for Huntington's disease. The deal, valued at up to $2.9 billion including a substantial $1 billion upfront payment, granted the partner exclusive rights to develop and commercialize the investigational assets. This strategic alliance highlights the continued heavy investment by major biopharmaceutical entities into the Global Gene Therapy Market, particularly for neurodegenerative conditions. The collaboration aims to leverage global commercial infrastructure to deliver potential disease-modifying therapies to a broader patient population suffering from this devastating genetic disorder.
• In April 2024, Pfizer Inc. obtained approval from the U.S. Food and Drug Administration for its adeno-associated virus vector-based gene therapy designed to treat adults with moderate to severe hemophilia B. This one-time treatment allows patients to produce their own Factor IX, significantly reducing bleeding rates and the need for regular prophylactic infusions. The approval positioned the pharmaceutical giant as a key competitor in the hemophilia segment of the Global Gene Therapy Market. The product's launch underscored the growing trend of large pharmaceutical companies successfully bringing complex genetic medicines to commercialization, providing long-term durability for patients with chronic bleeding disorders.
• In March 2024, Orchard Therapeutics received approval from the U.S. Food and Drug Administration for its hematopoietic stem cell gene therapy aimed at children with early-onset metachromatic leukodystrophy. This authorization marked the first approved treatment in the United States for this rare, fatal neurodegenerative condition. The therapy, which involves modifying a patient's own stem cells to deliver a functional gene, was introduced with a wholesale acquisition cost of $4.25 million, making it one of the most expensive medicines globally. This launch significantly expanded the Global Gene Therapy Market for rare pediatric diseases, offering a life-saving intervention where only supportive care previously existed.
• In January 2024, Vertex Pharmaceuticals and its partner secured a pivotal regulatory approval from the U.S. Food and Drug Administration for their gene-editing therapy to treat transfusion-dependent beta-thalassemia in patients aged 12 and older. This decision followed an earlier approval for sickle cell disease, firmly establishing the first CRISPR/Cas9-based treatment in the Global Gene Therapy Market. The therapy offers a potential functional cure, eliminating the need for lifelong blood transfusions for eligible patients. This milestone highlighted the rapid commercialization of gene-editing technologies and set a new precedent for curative genetic medicines in the hematology sector.

Key Market Players

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi
• F. Hoffmann-La Roche Ltd
• bluebird bio, Inc.
• Novartis AG
• uniQure NV.

By Vector Type	By Delivery Method	By Indication	By Region
Viral Vector Non-Viral Vector	In-Vivo Ex-Vivo	Rare Diseases Cancer Neurological Diseases Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gene Therapy Market, By Vector Type:

• Viral Vector
• Non-Viral Vector

• Gene Therapy Market, By Delivery Method:

• In-Vivo
• Ex-Vivo

• Gene Therapy Market, By Indication:

• Rare Diseases
• Cancer
• Neurological Diseases
• Others

• Gene Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE